Stay current in 5 minutes.

Expert-curated medical research tailored for your practice. The most impactful findings, delivered weekly.

Clinidence
HIGH IMPACTGRADE: HIGH

SGLT2 Inhibitors Reduce HF Hospitalizations in HFpEF

In 6,263 patients with HFpEF, dapagliflozin reduced the primary composite endpoint by 18% (HR 0.82)...

Clinical Bottom Line

Consider SGLT2 inhibitors for patients with HFpEF to reduce hospitalization risk...

Information overload is real.

Keeping up with medical literature shouldn't feel like a second job. The volume of new research is outpacing human capacity to review it.

1,500+
Papers published weekly per specialty
<5 hrs
Time physicians have for literature
70%
Feel behind on latest research

How Clinidence works

From raw research to actionable knowledge in three steps.

Smart Filters

We review 500+ papers weekly and utilize GRADE methodology to select the 10-15 most impactful findings for your specialty.

Swipe Through Cards

Review studies in seconds. Each card distills complex research into a scannable format with clear clinical takeaways.

Save What Matters

Swipe right to save practice-changing findings to your personal library. Build a reference database that travels with you.

Anatomy of a digest.

We've redesigned the medical abstract. No more wading through density. Every card is engineered for rapid comprehension and clinical application.

  • Impact Badges

    Instantly know if a finding is practice-changing, notable, or emerging.

  • Evidence Grading

    GRADE methodology scores each study from High to Very Low quality.

  • Clinical Bottom Line

    The 'so what?' — actionable takeaways you can apply immediately.

  • PubMed Source

    One tap to the full peer-reviewed article for deep feeling.

High Impact
GRADE: HIGH

SGLT2 Inhibitors Reduce HF Hospitalizations in HFpEF

In 6,263 patients with HFpEF, dapagliflozin reduced the primary composite endpoint by 18% (HR 0.82, 95% CI 0.73-0.92).

The benefit was consistent across prespecified subgroups, including patients with and without diabetes.

Clinical Bottom Line

Consider SGLT2 inhibitors for patients with HFpEF, regardless of diabetes status, to reduce risk of worsening heart failure.

NEJM • 2 weeks agoView Source →

12 Medical Specialties

Choose your focus. Get relevant research.

Cardiology

Heart failure, MI, AFib

Oncology

Cancer treatment, immunotherapy

Neurology

Stroke, dementia, MS

Nephrology

CKD, AKI, dialysis

Pulmonology

COPD, asthma, fibrosis

Endocrinology

Diabetes, thyroid, obesity

Gastroenterology

IBD, liver, GI disorders

Rheumatology

RA, lupus, autoimmune

Infectious Disease

HIV, sepsis, infections

Hematology

Lymphoma, leukemia

Psychiatry

Depression, schizophrenia

Emergency Med

Trauma, resuscitation

Free users: 1 specialty · Pro users: Unlimited

Unlock the full experience.

Get comprehensive access to medical research across all specialties.

  • Unlimited Specialties (Access all 12)
  • Custom Research Threads
  • Monthly Best Digests
  • Unlimited Archive Access
  • Advanced Topic Filters

Powered by PubMed

All content sourced directly from peer-reviewed literature.

Evidence-Based

Rigorous GRADE methodology applied to every finding.

Physician Reviewed

Automated curation validated by medical professionals.

Frequently Asked Questions

5 minutes. 12 specialties.
Infinite impact.

Join thousands of physicians who use Clinidence to stay at the forefront of their field without the burnout.